Merck, Gilead to co-develop combined HIV treatments
Merck and Gilead have announced a collaboration to investigate Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen.
Both the drugs are first-in-class medicines in late-stage clinical trials, have long half-lives and have demonstrated clinical activity at low dosages in clinical trials. The molecules are under trials as a combination regimen being administered orally as well as intravenously with long-acting formulations. The trials to evaluate the combination therapy are expe...
